Spring 2022 brought in some landmark blood cancer approvals from the FDA. Here is a roundup of the therapies recently approved by the FDA that patients may have missed.
As we head into the summer months, certain patients with blood cancer have more treatment options than ever before, as CAR-T cell therapies and other drugs were recently approved by the Food and Drug Administration (FDA). In some cases, these approvals are offering better outcomes than years-old standards of care.
In case you missed it, here are four drugs that were approved in the hematologic cancer space in recent months:
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.